6 assets in Mucopolysaccharidosis

Therapeutic assets addressing Mucopolysaccharidosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rituximab Mucopolysaccharidosis	Takeda	P4	BB (68)
Idursulfase Mucopolysaccharidosis	Takeda	P4	BB (65)
Human Immunoglobulins Mucopolysaccharidosis	Takeda	P4	B (62)
Methotrexate Mucopolysaccharidosis	Takeda	P4	B (60)
Busulfanum Mucopolysaccharidosis	Masonic Cancer Center, University of Minnesota	P2	B (57)
Cald Hr-D Mucopolysaccharidosis	Masonic Cancer Center, University of Minnesota	P2	CCC (53)